00766.000019.1

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:			Evaminan Malgamata A Waliaks		
SATOSHI KOIZUMI ET AL.			Examiner: Malgorzata A. Walicka Group Art Unit: 1652		
Application No.: 10/781,010			Group Art Ollit. 1032		
Filed:	February 18, 2004)			
For:	PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES	; ; ;	April 28, 2005		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the document listed on the enclosed Form PTO-1449. A copy of the cited portions of the document is enclosed, as is a copy of the published abstract (PMID 8756614). If the Examiner wishes for a complete copy of the document, such will be obtained and supplied upon receipt of request therefor.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 28, 2005 (Date of Deposit)

LAWRENCE S. PERRY

(Name of Attorney for Applicant)

Signature

April 28, 2005

Date of Signature

05/03/2005 MAHMED1 00000009 10781010

01 FC:1806

180.00 OP

The document was cited in the March 25, 2005 Office Action in Applicants' corresponding Chinese patent application. A copy of the Office Action and English translation are enclosed as well.

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Each item of information in this information disclosure statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Statement.

CONCLUSION

We also enclose a check for the required fee of \$180.00 to cover the Information Disclosure Statement under 37 C.F.R. 1.97(c)(2).

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Attorney for Applicants

Lawrence S. Perry

Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, New York 10112-3801

Facsimile: (212) 218-2200

LSP/ac

FORM PTO 14	49 (modified)		OVPE	ATTY DOCKET NO.	APPLIC	CATION NO.				
	U.S. DEPART PATENT AND	MENT OF COM	MERCE OFFICE	00766.000019.1	00766.000019.1 10/781,010					
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NAV 0 2 2005 LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Filing Date February 18, 2004 APPLICATION NO. 10/781,010 APPLICATION NO. 10/781										
	·		PARSH	February 18, 2	2004	GROUP 16	52			
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		OCUMENT NUMBER	DATE	NAME	CLAS	SS SUBCLASS	FILING DATE IF APPROPRIATE			
-				1						
•										
	FOREIGN PATENT DOCUMENTS									
		OCUMENT NUMBER	DATE	COUNTRY	CLAS	SS SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT			
										
			-							
			OTHER DOCUME	NT(S) (Including Author, Title, Date, Pertinent F	Pages, Etc.)					
	Ko	Ko, et al., "Biotransformation of Uridine Monophosphate (UMP) and Glucose to Uridine Diphosphate-Glucose (UDPG) by", Applied Biochemistry and Biotechnology, Vol. 60, No. 1								
	(19	(1996), pages 41 and 43								
			 							
		,								
EXAMINER				DATE CONSIDERED						

Sheet_1_ of _1_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.